Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report

Marilena Crescimanno, Carla Flandina, Gaetano Leto, Lorena Incorvaia, Fabio Fulfaro, Giuseppe Badalamenti, Lorena Incorvaia, Maria Vittoria Sepporta, Chiara Ancona, Giuseppe Badalamenti, Carla Flandina, Fabio Fulfaro, Marilena Crescimanno, Gaetano Leto, Chiara Ancona

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

This study was directed to assess the clinical impact of the circulating cathepsin L, cystatin C, activin A, and follistatin in breast cancer patients. The serum concentrations of these molecules were determined by immunoenzymatic assays, and their association with some clinico-pathological parameters of breast cancer progression was evaluated. Our results identified cystatin C and activin A as predictive markers for the presence of breast cancer and bone metastasis, respectively. Therefore, these proteins may have a clinical role as circulating biomarkers in the diagnosis and therapeutic monitoring of breast cancer patients.
Original languageEnglish
Pages (from-to)415-423
Number of pages9
JournalCancer Investigation
Volume34
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report'. Together they form a unique fingerprint.

Cite this